Steward Partners Investment Advisory’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-968
| Closed | -$5.65K | – | 3460 |
|
|
2022
Q4 | $5.65K | Sell |
968
-1,000
| -51% | -$5.26K | ﹤0.01% | 2734 |
|
|
2022
Q3 | $13K | Hold |
1,968
| – | – | ﹤0.01% | 2431 |
|
|
2022
Q2 | $8K | Hold |
1,968
| – | – | ﹤0.01% | 2614 |
|
|
2022
Q1 | $7K | Sell |
1,968
-4,009
| -67% | -$12.7K | ﹤0.01% | 2803 |
|
|
2021
Q4 | $19K | Sell |
5,977
-7,525
| -56% | -$25K | ﹤0.01% | 2356 |
|
|
2021
Q3 | $44K | Sell |
13,502
-2,517
| -16% | -$8.82K | ﹤0.01% | 1973 |
|
|
2021
Q2 | $68K | Sell |
16,019
-404,935
| -96% | -$1.71M | ﹤0.01% | 2773 |
|
|
2021
Q1 | $2.1M | Buy |
420,954
+345,943
| +461% | +$2.8M | 0.04% | 419 |
|
|
2020
Q4 | $948K | Sell |
75,011
-2,205
| -3% | -$25.1K | 0.02% | 578 |
|
|
2020
Q3 | $758K | Sell |
77,216
-1,217
| -2% | -$12K | 0.02% | 563 |
|
|
2020
Q2 | $780K | Buy |
78,433
+6,165
| +9% | +$59.1K | 0.02% | 519 |
|
|
2020
Q1 | $638K | Sell |
72,268
-5,115
| -7% | -$50.4K | 0.02% | 504 |
|
|
2019
Q4 | $713K | Buy |
77,383
+7,936
| +11% | +$56.2K | 0.02% | 536 |
|
|
2019
Q3 | $408K | Buy |
69,447
+3,305
| +5% | +$35.1K | 0.01% | 644 |
|
|
2019
Q2 | $793K | Buy |
66,142
+5,107
| +8% | +$54.9K | 0.03% | 438 |
|
|
2019
Q1 | $736K | Buy |
61,035
+2,350
| +4% | +$34.6K | 0.03% | 427 |
|
|
2018
Q4 | $736K | Buy |
58,685
+10,725
| +22% | +$148K | 0.04% | 400 |
|
|
2018
Q3 | $712K | Buy |
47,960
+4,700
| +11% | +$73.9K | 0.03% | 427 |
|
|
2018
Q2 | $728K | Buy |
43,260
+13,260
| +44% | +$258K | 0.04% | 373 |
|
|
2018
Q1 | $687K | Buy |
30,000
+14,350
| +92% | +$319K | 0.05% | 346 |
|
|
2017
Q4 | $404K | Buy |
15,650
+10,650
| +213% | +$214K | 0.03% | 406 |
|
|
2017
Q3 | $73K | Buy |
5,000
+2,550
| +104% | +$37K | 0.01% | 604 |
|
|
2017
Q2 | $34K | Hold |
2,450
| – | – | ﹤0.01% | 729 |
|
|
2017
Q1 | $41K | Buy |
+2,450
| New | +$29.4K | 0.01% | 601 |
|
Steward Partners Investment Advisory's CNCE Position: Q1 2023 in Review
Steward Partners Investment Advisory sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 968 shares — an estimated $5.65K sold.
Steward Partners Investment Advisory first reported a position in CNCE in Q1 2017 and held it in 24 quarters. The position peaked at $2.1M in Q1 2021. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Steward Partners Investment Advisory reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Steward Partners Investment Advisory sold 968 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $5.65K.
- Steward Partners Investment Advisory first reported a position in Concert Pharmaceuticals, Inc. in Q1 2017 and held it in 24 quarters.
- Steward Partners Investment Advisory's Concert Pharmaceuticals, Inc. position peaked at $2.1M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Steward Partners Investment Advisory's 13F filing for Q1 2023, filed 15 May 2023.